A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This study is tracking how well canakinumab works whether it's used as a first biologic or after other biologics have already been tried — given where I am in my treatment history, which of those situations applies to me, and does that affect whether this study would be relevant to my situation?
2. 2One of the things this study is measuring is whether patients are able to reduce or stop steroids while on canakinumab — if I'm currently on steroids for my FMF or Still's disease, is that something we could realistically aim for, and how would you monitor whether it's safe to taper?
3. 3The study also tracks patients who discontinue canakinumab within 6 months — what are the most common reasons patients stop this medication, and how would we handle it if I needed to stop after starting?
4. 4Since this trial is listed as 'Phase NA,' which usually means it's observational rather than a traditional drug trial, can you explain what that means for me practically — would I be receiving canakinumab as part of my standard care, and would anything change about how I'm treated compared to not being in the study?
5. 5The study is measuring outcomes in both Familial Mediterranean Fever and Still's disease separately — since my diagnosis is specifically [my condition], how confident are you that the results being collected here would help inform decisions about my own treatment going forward?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.